Breaking News

AGC Biologics Launches BravoAAV and ProntoLVV Platforms for CGTs

Designed to provide flexible and accelerated vector development and manufacturing for cell and gene therapy programs.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AGC Biologics, a global biopharmaceutical CDMO, launched its BravoAAV and ProntoLVV viral vector platforms. The new platforms leverage the company’s Lentiviral vector (LVV) and Adeno-Associated Viral vector (AAV) development, manufacturing and analytical experience to offer fast, efficient and reproducible clinical and commercial GMP production and release. The company’s process and capsid-specific platform methods aim to accelerate development timelines, delivering GMP product in nine months. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters